NCT03185143已完成2 期
Randomized, Double-Blind, and Placebo-Controlled Study to Assess a Single Dose of Low-Dose Naltrexone and Acetaminophen Combination Versus Sumatriptan in the Acute Treatment of Migraine With Nausea
Allodynic Therapeutics, Inc1 个研究点 分布在 1 个国家目标入组 36 人开始时间: 2017年6月27日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 36
- 试验地点
- 1
- 主要终点
- The proportion of patients having no headache pain at 2 hours.
研究概览
简要总结
This proof-of-concept study compares side-by-side low-dose naltrexone and acetaminophen combination to sumatriptan in the acute treatment of migraine.
详细描述
The study consists of a screening visit, outpatient treatment of a moderate or severe migraine attack with a single dose of the study drug within 8 weeks, and End-of-Study Visit 2-7 days after dosing.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female 18 to 65 years of age.
- •History of migraine with or without aura according to the International Classification of Headache Disorders (ICHD)-3rd edition (beta version) for at least one-year with first migraine prior to age
- •Migraine-associated nausea with ≥half the migraine attacks.
- •2 - 8 migraines per month in each of the previous 3 months.
- •The patient is able to complete study questionnaires, comply with the study requirements and restrictions, and willing to provide written informed consent and authorize HIPAA.
- •The female patient who is premenopausal or postmenopausal less than 1 year, or have not had surgical sterilization (i.e., tubal ligation, partial or complete hysterectomy) must have a negative urine pregnancy test, be non-lactating, and commit to using 2 methods of adequate and reliable contraception throughout the study and for 28 days after taking the last dose of the study drug (e.g., barrier with additional spermicidal, intra-uterine device, hormonal contraception). Male patients must be surgically sterile or commit to the use of 2 different methods of birth control during the study and for 28 days after the study.ice, hormonal contraception).
排除标准
- •The patient in the opinion of the investigator may have medication-overuse headaches (as defined by ICHD - 3 beta criteria for medication-overuse headache) during the preceding 3 months.
- •The patient in the opinion of the investigator has chronic migraine (as defined by ICHD - 3 beta criteria for chronic migraine) during the preceding 3 months.
- •History of cluster headaches or neurologically complicated migraine (hemiplegic, basilar, retinal, ophthalmoplegic).
- •Initiation or change in medications with possible migraine prophylactic effects during 3 months before inclusion into the trial (E.g., calcium channel blockers, tricyclic antidepressants, beta-blockers, or Botox).
- •Use of opiates or barbiturates more than 3 days per month.
- •Any concurrent medical or psychiatric condition, this includes, but is not limited to chronic unstable debilitating diseases, significant renal or hepatic impairment.
- •The patient has a history within the previous 3 years of abuse of any drug, prescription, illicit, or alcohol.
- •The Female patient is pregnant or breast-feeding. The Male patient is not practicing 2 different methods of birth control with their partner during the study, and for 28 days after the investigational drug last dose or will not remain abstinent during the study, and for 28 days after the last dose.
- •The patient has known-hypersensitivity reaction to any of the components of the investigational drug.
- •Consumption of analgesic medication or muscle relaxants (including all benzodiazepines) for other conditions on a regular basis.
- •The patient has used emergency care treatment more than 3 times in the previous 6 months.
- •The patient has participated in another study with an investigational drug within 30 days prior to randomization and/or plan to participate during the study.
- •The patient has a history of congenital heart disease, cardiac arrhythmias, or cardiovascular disease, e.g., ischemic heart disease (e.g., stable angina pectoris, unstable angina, vasospastic angina, myocardial infarction or silent myocardial ischemia), cerebrovascular syndromes (e.g., strokes of any type or transient ischemic attacks), peripheral vascular disease, ischemic bowel disease, or Raynaud syndrome.
- •Uncontrolled hypertension (sitting >160 mmHg systolic pressure or >95mmHg diastolic pressure).
- •The patient, in the investigator's opinion, is likely to have unrecognized cardiovascular or cerebrovascular disease.
- •History of epilepsy. Allergy to sulfonamides.
- •Consumption of monoamine oxidase inhibitor (MAOI) drug, tricyclic antidepressant, selective serotonin reuptake inhibitor (SSRI) or Serotonin Noradrenaline Reuptake Inhibitor (SNRI).
研究组 & 干预措施
Naltrexone and Acetaminophen Combination
Experimental
干预措施: Naltrexone and Acetaminophen Combination (Drug)
Sumatriptan 100 mg
Active Comparator
干预措施: Sumatriptan 100 mg (Drug)
Placebo
Placebo Comparator
干预措施: Placebo (Drug)
结局指标
主要结局
The proportion of patients having no headache pain at 2 hours.
时间窗: 2 hours
Measured by asking the patients to self-report the current status of their headache pain on a four-point Likert scale (i.e., 0=none, 1=mild, 2=moderate, 3=severe).
The proportion of patients having the absence of the most bothersome migraine-associated symptom at 2 hours.
时间窗: 2 hours
The most bothersome migraine-associated symptom is prospectively identified at baseline. It is measured by asking the patients to self-report the current status of their associated symptom as present or absent.
次要结局
- The proportion of patients having the absence of nausea, photophobia, phonophobia, and neck/shoulder pain at 2 hours.(24 and 48 hours)
- The proportion of patients who used rescue medications within 24 hours.(24 hours)
- The proportion of patients who are "sustained pain-free" at 24-hours and 48-hours.(48 hours.)
- The proportion of patients who had headache pain relapse within 48 hours(48 hours)
- The proportion of patients who experienced adverse events(48 hours)
研究者
研究点 (1)
Loading locations...
相似试验
撤回
4 期
A Comparative Efficacy Trial of IV Acetaminophen Versus IV Ketorolac for Emergency Department Treatment of Generalized HeadacheHeadacheNCT03472872Spectrum Health - Lakeland
已完成
2 期
Acetaminophen/Naproxen Sodium Dose Ranging StudyPainNCT04447040Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division304
已完成
1 期
A Study to Characterize the Abuse Liability of ALO-02 in Healthy, Non-Dependent, Recreational Opioid Users When ALO-02 Capsules Are Crushed and SnortedHealthyNCT01775189Pfizer45
已完成
2 期
A Study Comparing Oxycodone to Oxycodone/Naloxone in Moderate to Severe, Chronic Cancer PainPainCancerConstipationNCT00513656Mundipharma Research GmbH & Co KG230
已完成
3 期
A Study to Evaluate a Fixed Combination of Acetaminophen/Naproxen Sodium in Acute Postoperative Pain Following BunionectomyPainNCT05868122Johnson & Johnson Consumer Inc. (J&JCI)143